Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.52 Min. order: 1 piece ★★★★★ 4.0 (275 reviews) Sold : Login>>
Novo Nordisk advances obesity candidate to late-stage program after weight loss of less than 12% US$ 23.78 Min. order: 1 piece ★★★★★ 4.0 (194 reviews) Sold : Login>>
Based on the early promising data for injectable cagrilintide-semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP-1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 US$ 25.36 Min. order: 1 piece ★★★★★ 4.8 (220 reviews) Sold : Login>>
Novo Nordisk Aims for the Top: CagriSema Poised for Breakthrough US$ 22.88 Min. order: 1 piece ★★★★★ 4.9 (275 reviews) Sold : Login>>
Novo Nordisk presents new Phase III data for next-gen amylin cagrilintide US$ 24.64 Min. order: 1 piece ★★★★★ 4.5 (281 reviews) Sold : Login>>
Topline data from REDEFINE 1 found CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. 🔗https://t.co/JA9E3FpCsN #ObesityManagement # US$ 27.69 Min. order: 1 piece ★★★★★ 4.6 (110 reviews) Sold : Login>>